Dr. Dinesh S. Patel
Ph.D., CChem., FRSC (Lon.)
MANAGING DIRECTOR & CEO

THEMIS
MEDICARE

TML: CS: 2012-13:

5th February, 2013

The Vice President
Listing Department,
National Stock Exchange of India Ltd.
"Exchange Plaza", Bandra – Kurla Complex,
Bandra – East,
Mumbai- 400 051.

Kind Attn: Mr. Hari K

Dear Sirs,

Sub: Unaudited Financial results for the quarter ended 31st December, 2012.

The Board of Directors at its meeting held today, considered and approved Unaudited Financial Results for the quarter ended 31st December, 2012 together with Limited Review Report by the Statutory Auditors of the Company thereon which were earlier approved by the Audit Committee of the Company at its meeting held before the Board Meeting.

A copy of Unaudited Financial Results for the quarter ended 31st December, 2012 is enclosed for your perusal.

This may be taken as compliance of the Listing Agreement; the Company has entered with your stock exchange.

Kindly acknowledge.

Thanking you,

Yours faithfully,
For **THEMIS MEDICARE LTD.**

DR.DINESH S.PATEL
MANAGING DIRECTOR & CEO

THEMIS MEDICARE LTD

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat.
Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

PART I (₹ in Lakhs)

Statement of Unaudited Financial Results for the period ended 31st December 2012.

	Particulars	Quarter ended			Current period ended	Previous period ended	Previous year ended
		(31/12/2012)	(30/09/2012)	(31/12/2011)	(31/12/2012)	(31/12/2011)	(31/03/2012)
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations						
	(a) Net sales/income from operations (Net of excise duty)	3,435.64	3,959.18	4,076.71	12,094.40	10,067.39	13,485.68
	(b) Other operating income	46.55	54.06	209.23	199.29	259.34	316.12
	Total income from operations (net)	3,482.19	4,013.24	4,285.94	12,293.69	10,326.73	13,801.80
2	Expenses						
	(a) Cost of materials consumed	1,632.57	2,319.11	2,540.53	6,535.17	6,215.89	8,306.20
	(b) Purchases of stock-in-trade	204.78	156.29	260.94	419.15	581.55	592.86
	(c) Changes in inventories of finished goods,						
	work-in-progress and stock-in-trade	99.91	(712.63)	(96.89)	(389.64)	605.21	512.92
	(d) Employee benefits expense	584.56	585.76	526.42	1,728.22	1,583.39	2,097.60
	(e) Depreciation and amortisation expense	145.62	152.57	133.27	432.01	381.32	508.02
	(f) Other expenses(Any item exceeding 10% of the total	961.33	1,083.45	1,086.43	3,166.85	3,185.17	4,137.91
	expenses relating to continuing operations to be shown separately)						
	Total expenses	3,628.77	3,584.55	4,450.70	11,891.76	12,552.53	16,155.51
3	Profit / (Loss) from operations before other						
	income, finance costs and exceptional items (1-2)	(146.58)	428.69	(164.76)	401.93	(2,225.80)	(2,353.71)
4	Other income	13.02	2.67	21.99	341.64	222.91	217.82
5	Profit / (Loss) from ordinary activities before						
	finance costs and exceptional items (3 + 4)	(133.56)	431.36	(142.77)	743.57	(2,002.89)	(2,135.89)
6	Finance costs	277.66	428.15	249.69	1,154.65	956.14	1,348.08
7	Profit / (Loss) from ordinary activities after						
	finance costs but before exceptional items (5 + 6)	(411.22)	3.21	(392.46)	(411.08)	(2,959.03)	(3,483.97)
8	Exceptional items	-	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(411.22)	3.21	(392.46)	(411.08)	(2,959.03)	(3,483.97)
10	Tax expense	(9.73)	(10.42)	-	(29.30)		(16.57)
11	Net Profit / (Loss) from ordinary activities after tax (9 - 10)	(401.49)	13.63	(392.46)	(381.78)	(2,959.03)	(3,467.40)
12	Extraordinary items (net of tax expense Rs. NIL)	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	(401.49)	13.63	(392.46)	(381.78)	(2,959.03)	(3,467.40)
14	Share of profit / (loss) of associates	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit						
	/(loss) of associates (13+14 +15).	(401.49)	13.63	(392.46)	(381.78)	(2,959.03)	(3,467.40)
17	Paid-up equity share capital- Face Value Rs. 10/- each	805.05	805.05	805.05	805.05	805.05	805.05
18	Reserve excluding Revaluation Reserves as per balance sheet of						4,370.66
	previous accounting year						
19	Earnings per share (before extraordinary items)						
	(a) Basic	(4.99)	0.17	(4.87)	(4.74)	(36.76)	(43.07)
	(b) Diluted	(4.75)	0.17	(4.87)	(4.52)	(36.76)	(43.07)
19ii	Earnings per share (after extraordinary items)						
	(a) Basic	(4.99)	0.17	(4.87)	(4.74)	(36.76)	(43.07)
	(b) Diluted	(4.75)	0.17	(4.87)	(4.52)	(36.76)	(43.07)





PART II

Select Information for the period ended 31/12/2012

	Particulars	Quarter ended			Current period ended	Previous period ended	Previous year ended
		(31/12/2012)	(30/09/2012)	(31/12/2011)	(31/12/2012)	(31/12/2011)	(31/03/2012)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	- Number of shares	2439685	2439685	2444029	2439685	2444029	2439685
	- Percentage of shareholding	30.30	30.30	30.36	30.30	30.36	30.30
2	Promoters and Promoter Group Shareholding						
	a) Pledged / Encumbered						
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total						
	shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total						
	share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non - encumbered						
	- Number of shares	5610815	5610815	5606471	5610815	5606471	5610815
	- Percentage of shares (as a % of the total						
	shareholding of the Promoter and						
	Promoter group)	100	100	100	100	100	100
	- Percentage of shares (as a % of the total						
	share capital of the company)	69.70	69.70	69.64	69.70	69.64	69.70

	Particulars	3 months ended (31/12/2012)
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	-
	Received during the quarter	-
	Disposed of during the quarter	-
	Remaining unresolved at the end of the quarter	-

NOTES :

1. The Company has only one segment namely pharmaceuticals, hence no separate segmentwise disclosure has been made.
2. 4 lac fully convertible preferential warrants issued to promoters during the earlier quarter will be converted into Equity Shares on 16.01.2014.
3. The above results have been subjected to ""Limited Review" by the Statutory Auditors of the Company in compliance with the requirement of the Listing Agreement with Stock Exchanges.
4. The above results were reviewed by the Audit Committee and aproved by the Board of Directors at its meeting held on 5th February 2013.

M. T. ANKLESHWARIA & CO. CHARTERED ACCOUNTANTS M No. 30128 MUMBAI.

As per Review Report attached
For M. T. Ankleshwaria & Co.
Chartered Accountants

Madhu T. Ankleshwaria
Proprietor

By Order of the Board
For THEMIS MEDICARE LTD

Dr. DINESH PATEL
(Managing Director & CEO)

Place : Mumbai
Date : 05 /02 /2013

M. T. ANKLESHWARIA & CO.
CHARTEREDACCOUNTANTS
MADHU T. ANKLESHWARIA
B.COM. (HONS) F.C.A.

TEL: 2614 9392
7 GOKUL NIWAS,
47, BAJAJ ROAD,
VILE PARLE (WEST),
MUMBAI - 400 056.

The Board of Directors,
Themis Medicare Limited,
Mumbai.

Dear Sirs,

Re: LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS OF THEMIS MEDICARE LTD FOR THE QUARTER ENDED 31st DECEMBER, 2012.

"We have reviewed the accompanying statement of Unaudited financial results of **THEMIS MEDICARE LTD.** for the quarter ended 31st December, 2012. This financial statement is the responsibility of the Company's Management and has been approved by the Board of Directors at the meeting held on 5th February, 2013. Our responsibility is to express a conclusion on this interim financial information based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *"Review of interim Financial Information Performed by the Independent Auditor of the Entity"*. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequentially does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an Audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement."

M. T. ANKLESHWARIA & CO. CHARTERED ACCOUNTANTS M. No. 30128 MUMBAI.

For **M.T.ANKLESHWARIA & CO,**
CHARTERED ACCOUNTANTS

MADHU T. ANKLESHWARIA
PROPRIETOR

Place: Mumbai
Date: 05.02.2013